Terms: = Brain cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
205 results:
1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
2. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and treatment Implications.
Li J; Zhang L; Ge T; Liu J; Wang C; Yu Q
Drug Des Devel Ther; 2024; 18():829-843. PubMed ID: 38524877
[TBL] [Abstract] [Full Text] [Related]
3. [Systemic treatment of adult gliomas: a narrative review].
Mangel L
Magy Onkol; 2024 Mar; 68(1):67-75. PubMed ID: 38484377
[TBL] [Abstract] [Full Text] [Related]
4. Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer's disease.
Zhang M; Zhang Z; Li H; Xia Y; Xing M; Xiao C; Cai W; Bu L; Li Y; Park TE; Tang Y; Ye X; Lin WJ
Transl Neurodegener; 2024 Jan; 13(1):1. PubMed ID: 38173017
[TBL] [Abstract] [Full Text] [Related]
5. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
Zhao S; Zhang M; Zhang Q; Wu J; Dai H
BMC Cancer; 2024 Jan; 24(1):6. PubMed ID: 38166698
[TBL] [Abstract] [Full Text] [Related]
6. STING activation counters glioblastoma by vascular alteration and immune surveillance.
Joseph JV; Blaavand MS; Cai H; Vernejoul F; Knopper RW; Lindhardt TB; Skipper KA; Axelgaard E; Reinert L; Mikkelsen JG; Borghammer P; Degn SE; Perouzel E; Hager H; Hansen B; Kalucka JM; Vendelbo M; Paludan SR; Thomsen MK
Cancer Lett; 2023 Nov; 579():216480. PubMed ID: 37931834
[TBL] [Abstract] [Full Text] [Related]
7. The role of immune subtyping in glioma mRNA vaccine development.
Guterres A; Abrahim M; da Costa Neves PC
Immunotherapy; 2023 Sep; 15(13):1057-1072. PubMed ID: 37431617
[TBL] [Abstract] [Full Text] [Related]
8. Cascade-Responsive 2-DG Nanocapsules Encapsulate aV-siCPT1C Conjugates to Inhibit Glioblastoma through Multiple Inhibition of Energy Metabolism.
Zhang Y; Ren Y; Xu H; Li L; Qian F; Wang L; Quan A; Ma H; Liu H; Yu R
ACS Appl Mater Interfaces; 2023 Mar; 15(8):10356-10370. PubMed ID: 36787514
[TBL] [Abstract] [Full Text] [Related]
9. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
Yao C; Wu S; Kong J; Sun Y; Bai Y; Zhu R; Li Z; Sun W; Zheng L
Cancer Biol Med; 2023 Jan; 20(1):25-43. PubMed ID: 36647777
[TBL] [Abstract] [Full Text] [Related]
10. Guggulsterone Promotes Nasopharyngeal Carcinoma Cells Exosomal Circfip1L1 to Mediate miR-125a-5p/VEGFA Affecting Tumor Angiogenesis.
Zhou T; Zhao S; Tang S; Wang Y; Wu R; Zeng X; Yang P; Zhang X; Tian X
Curr Mol Pharmacol; 2023; 16(8):870-880. PubMed ID: 36635928
[TBL] [Abstract] [Full Text] [Related]
11. vegfr-TKI treatment for radiation-induced brain injury after gamma knife radiosurgery for brain metastases from renal cell carcinomas.
Noda R; Akabane A; Kawashima M; Uchino K; Tsunoda S; Segawa M; Inoue T
Jpn J Clin Oncol; 2023 Mar; 53(4):355-364. PubMed ID: 36579769
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).
Sheng X; Ye D; Zhou A; Yao X; Luo H; He Z; Wang Z; Zhao Y; Ji Z; Zou Q; He C; Guo J; Tu X; Liu Z; Shi B; Liu B; Chen P; Wei Q; Hu Z; Zhang Y; Jiang K; Zhou F; Wu D; Fu C; Li X; Wu B; Wang L; Qin S; Li G; Liu Y; Guo H; Chen K; Zhang D; Wang G; Ding L; Wang Y; Yuan X; Guo J
Eur J Cancer; 2023 Jan; 178():205-215. PubMed ID: 36459768
[TBL] [Abstract] [Full Text] [Related]
13. Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors.
Zhang F; Zhang Q; Zhu J; Yao B; Ma C; Qiao N; He S; Ye Z; Wang Y; Han R; Feng J; Wang Y; Qin Z; Ma Z; Li K; Zhang Y; Tian S; Chen Z; Tan S; Wu Y; Ran P; Wang Y; Ding C; Zhao Y
Cell Res; 2022 Dec; 32(12):1047-1067. PubMed ID: 36307579
[TBL] [Abstract] [Full Text] [Related]
14. Hypoxia-Driven M2-Polarized Macrophages Facilitate cancer Aggressiveness and Temozolomide Resistance in Glioblastoma.
Zhang G; Tao X; Ji B; Gong J
Oxid Med Cell Longev; 2022; 2022():1614336. PubMed ID: 36046687
[TBL] [Abstract] [Full Text] [Related]
15. N-myc Downstream-Regulated Gene 1 (NDRG1) Regulates Vascular Endothelial Growth Factor A (VEGFA) and Malignancies in Glioblastoma Multiforme (GBM).
Zhang X; Chen Q; Li Y; Chen H; Jiang Q; Hu Q
Biomed Res Int; 2022; 2022():3233004. PubMed ID: 35813230
[TBL] [Abstract] [Full Text] [Related]
16. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK; Rumble RB; Van Veldhuizen PJ; Al-Ahmadie H; Emamekhoo H; Hauke RJ; Louie AV; Milowsky MI; Molina AM; Rose TL; Siva S; Zaorsky NG; Zhang T; Qamar R; Kungel TM; Lewis B; Singer EA
J Clin Oncol; 2022 Sep; 40(25):2957-2995. PubMed ID: 35728020
[TBL] [Abstract] [Full Text] [Related]
17. Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the vegfr2/Nrf2 Pathway.
Xia L; Gong M; Zou Y; Wang Z; Wu B; Zhang S; Li L; Jin K; Sun C
Oxid Med Cell Longev; 2022; 2022():9925919. PubMed ID: 35602105
[TBL] [Abstract] [Full Text] [Related]
18. Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature.
Zhu Y; Zhao L; Xu Y; Zhan W; Sun X; Xu X
Ann Palliat Med; 2022 Jan; 11(1):394-400. PubMed ID: 35144430
[TBL] [Abstract] [Full Text] [Related]
19. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.
Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF
Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487
[TBL] [Abstract] [Full Text] [Related]
20. Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells.
Li Y; He F; Zhang Y; Pan Z
Dis Markers; 2022; 2022():3833489. PubMed ID: 35069931
[TBL] [Abstract] [Full Text] [Related]
[Next]
